NBIX News and Press, Neurocrine Biosciences Inc. From 08/01/23

2023-08-01 07:18:53 ET Neurocrine Biosciences press release ( NASDAQ: NBIX ): Q2 Non-GAAP EPS of $1.25 beats by $0.13 . Revenue of $452.7M (+19.7% Y/Y) beats by $4.72M . INGREZZA (valbenazine) Second Quarter Net Product Sales of $440 Million Representing...

Neurocrine Biosciences Reports Second Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance PR Newswire INGREZZA ® (valbenazine) Second Quarter Net Product Sales of $440 Million Representing 26% Year-Over-Year Growth INGREZZA ®...

2023-07-31 14:33:35 ET Neurocrine Biosciences ( NASDAQ: NBIX ) is scheduled to announce Q2 earnings results on Tuesday, August 1st, before market open. The consensus EPS Estimate is $1.12 (+33.3% Y/Y) and the consensus Revenue Estimate is $447.98M (+18.5% Y/Y). Over th...

2023-07-31 10:46:05 ET Major earnings expected before the bell on Tuesday include: Caterpillar ( CAT ) Enterprise Products Partners ( EPD ) Altria Group ( MO ) Merck & Co. ( MRK ) Pfizer ( PFE ) For further details see: Notable ear...

Neurocrine Biosciences Announces Appointment of Christine A. Poon to Board of Directors PR Newswire SAN DIEGO , July 11, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it appointed Christine A. Poon , a business leader w...

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2023 Financial Results PR Newswire Conference Call and Webcast Scheduled for Tuesday, August 1 SAN DIEGO , July 11, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasda...

2023-07-07 14:25:19 ET BMO Capital Markets has upgraded Neurocrine Biosciences ( NASDAQ: NBIX ) to market perform, citing its "improved confidence" in the "short-term durability" of the company's neurological drug Ingrezza, also known as valbenazine. The investment bank said the...

Diurnal Ltd., a Neurocrine Biosciences Company, Presents Phase 3 Extension Study Data for Modified-Release Hydrocortisone in Patients with Congenital Adrenal Hyperplasia at ENDO 2023 PR Newswire SAN DIEGO , June 15, 2023 /PRNewswire/ -- Diurnal Ltd., a Neurocrine...

Neurocrine Biosciences to Present at the Goldman Sachs 44th Annual Global Healthcare Conference PR Newswire SAN DIEGO , June 8, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Goldman Sachs 44 th Annual Global Healthcare C...

Neurocrine Biosciences Presents INGREZZA® (valbenazine) Capsules Data on Tardive Dyskinesia Improvement Regardless of Baseline Antipsychotic Use at 2023 Psych Congress Elevate PR Newswire SAN DIEGO , June 2, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc...